Related Experiment Videos
Statins and fibrates for preventing melanoma
R P Dellavalle1, A Drake, M Graber
1Denver Veterans Affairs Medical Center, Dermatology, 1055 Clermont Street, Mail Stop 165, Denver, Colorado 80220, USA. robert.dellavalle@uchsc.edu
The Cochrane Database of Systematic Reviews
|October 20, 2005
Summary
Lipid-lowering medications like statins and fibrates may offer some protection against melanoma, but results were not statistically significant. Further research is needed to confirm their preventative effects for melanoma.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Advanced melanoma treatment remains a challenge.
- Emerging evidence suggests lipid-lowering drugs may prevent melanoma.
- In vitro, case-control, and animal studies support this hypothesis.
Purpose of the Study:
- To evaluate the impact of statin and fibrate medications on melanoma outcomes.
- Assessing the potential of lipid-lowering drugs in melanoma prevention.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) of statins or fibrates.
- Searched multiple databases including Cochrane, MEDLINE, EMBASE, and CANCERLIT.
- Included trials with at least four years of therapy and random allocation.
Main Results:
- 16 RCTs (62,197 participants) provided melanoma outcome data.
- Statins showed an odds ratio of 0.90; fibrates showed 0.58, neither statistically significant.
- Lovastatin showed a potential reduction in melanoma incidence in one subgroup analysis (OR 0.52).
Conclusions:
- Current RCT data do not rule out a melanoma-preventive effect of statins and fibrates.
- Observed reductions in melanoma incidence were not statistically significant.
- Limiting ultraviolet radiation exposure remains the primary method for melanoma risk reduction.